Checks pancreatic cancer risk after starting exenatide in type 2 diabetes
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at whether starting exenatide (a type 2 diabetes medicine) is linked to a higher or lower risk of pancreatic cancer compared with other similar diabetes medicines. It uses people’s prescription and medical record history to compare risks over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older at the time their study uses as your start date
- Have diabetes-related prescription and health records available for at least 12 months before your start date
- Have a diagnosis of type 2 diabetes (T2DM) on or before your start date
- For the exenatide group: start exenatide within the study window after first using a different type of glucose-lowering medicine
- For the comparison group: start a different glucose-lowering medicine (not certain other diabetes drugs) within the study window
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a plan to monitor and manage blood sugar in people with pancreatic ductal cancer who are starting a specific chemotherapy regimen (FOLFIRINOX). The goal is to prevent or address high blood sugar during treatment, which may help people stay on therapy safely.
This trial studies how pancreatic cancer affects blood sugar and the risk of developing diabetes after surgery. Patients who have their pancreas removed will provide blood and tissue samples to help understand this link.
This study is looking at blood or tissue samples from people with pancreatic cancer and from those without it. The goal is to find ways to detect the cancer earlier.
This trial uses MRI and endoscopic ultrasound to look for early signs of pancreatic cancer in people who have a high risk due to their genes or family history. Finding it early may lead to better treatment options.
This study looks at how certain genes affect the risk of type 2 diabetes and how well the drug exenatide (a GLP-1 receptor agonist) works in Chinese patients. It aims to see if your genetic makeup can predict how you will respond to treatment.
This trial studies how exenatide affects blood sugar in pregnant people with gestational diabetes who do not need medication yet. The goal is to understand how the medicine works in the body during pregnancy, which may help improve future treatment decisions.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.